Skip to main content
Clinical Trials/NCT07292987
NCT07292987
Recruiting
Not Applicable

Implementation and Evaluation of a Post-diagnostic Announcement Protocol at the CRMR RefeRet of the Quinze-Vingts National Ophthalmology Hospital

Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts1 site in 1 country80 target enrollmentStarted: December 1, 2025Last updated:

Overview

Phase
Not Applicable
Status
Recruiting
Sponsor
Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
Enrollment
80
Locations
1
Primary Endpoint
Patient Satisfaction via PREM at 12 months

Overview

Brief Summary

This study explores whether adding early nurse-led and psychological support after the diagnosis of retinitis pigmentosa (RP) can improve patient experience and emotional well-being. RP is a rare, progressive eye disease often diagnosed after a long and difficult process, and receiving the diagnosis can be emotionally distressing.

Eighty newly diagnosed adults will be randomly assigned to either usual care or an enhanced pathway that includes early follow-up with a nurse, structured emotional monitoring, and a psychologist visit at six months.

The study aims to determine if this structured support improves patient satisfaction and reduces anxiety and depression compared with standard care.

Detailed Description

Retinitis pigmentosa (RP) is a rare genetic disease causing progressive vision loss. The announcement of diagnosis is a key moment that may trigger anxiety or depression, yet post-diagnostic care in ophthalmology often remains limited to medical information.

This prospective, monocentric, randomized study at the Quinze-Vingts National Ophthalmology Hospital tests a structured post-diagnostic support pathway that combines early nurse-led follow-up and systematic psychological support.

Eighty newly diagnosed patients aged 18-65 will be randomized into two parallel groups. The experimental group will receive early nurse consultations at 15 days and 6 months, psychological follow-up at 6 months, and repeated HADS assessments. The control group will receive usual care.

The primary outcome is patient satisfaction at 12 months (PREM). Secondary outcomes include changes in anxiety and depression (HADS) and feasibility feedback from nursing staff (RETEX).

Findings will inform the design of sustainable, multidisciplinary care models for rare eye diseases.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Supportive Care
Masking
None

Eligibility Criteria

Ages
18 Years to 65 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Diagnosed with retinitis pigmentosa (RP) and followed at the Quinze-Vingts Rare Eye Disease Center, with diagnosis made after the project begins
  • Aged 18 to 65 years
  • Male or female
  • French-speaking
  • Have a phone number
  • Reside in France

Exclusion Criteria

  • Pregnant women
  • Participants enrolled in a therapeutic clinical trial within the past 12 months
  • Individuals deprived of liberty by judicial or administrative decision
  • Adults under legal protection or unable to provide informed consent
  • Individuals with other medical conditions or taking treatments that could interfere with study evaluations

Arms & Interventions

Usual care group

Active Comparator

Intervention: Usual Care (Behavioral)

Enhanced care group

Experimental

Intervention: Enhanced post-diagnostic support (Behavioral)

Outcomes

Primary Outcomes

Patient Satisfaction via PREM at 12 months

Time Frame: 12 months

Difference in patient satisfaction via PREM (Patient Reported Experience Measure) at 12 months between the two arms. Items were rated on a 5-point Likert scale ranging from 1 (extremely worse than expected) to 5 (better than expected). Higher scores indicate a better perceived quality of care and psychological support.

Secondary Outcomes

  • Psychological impact after post-diagnostic support via HADS(15 days, 6 months and 12 months after diagnosis)
  • Feasibility and staff experience of implementing enhanced post-diagnostic support via RETEX and observation log(15 days, 6 months and 12 months after diagnosis)

Investigators

Sponsor
Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials